Back to Results
First PageMeta Content
Clinical research / Immunosuppressants / Science / Efalizumab / Autoimmune diseases / Progressive multifocal leukoencephalopathy / Psoriasis / Placebo / Clinical trial / Medicine / Health / Pharmacology


Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 2 to Wave 1 Case Study Report 1:b:iii: Efalizumab Multi-Criteria Decision Analysis: Decision
Add to Reading List

Document Date: 2014-07-16 01:09:14

Open Document

File Size: 849,13 KB

Share Result on Facebook

Company

Pfizer / AEs / Merck Serono / Catalyze Limited / /

Event

Product Recall / Product Issues / /

MedicalCondition

aseptic meningitis / haemolytic anemia / Severe Psoriasis / arthralgia / psoriatic arthritis / inflammatory polyradiculopathy / intersticial lung disease / Serious Infections / Severe Thrombocytopenia / progressive multifocal leukoencephalopathy / severe chronic plaque psoriasis / European ConsorTium Intersticial Lung Disease / psoriasis / patients exhibiting hypersensitivity / infections / back pain / dose-related acute flu / /

Organization

European Medicines Agency / European Commission / London School of Economics / European Medicines Agency On behalf of PROTECT Work Package / European Union / Imperial College / /

Person

Raptive / Larry Phillips / Nan Wang / Diana Hughes / Alain Micaleff / Kimberley Hockley / Nikolaos Zafiropoulos / /

Position

model / Physician / ConsorTium EXECUTIVE / /

Product

MA suspension / efalizumab / Market Authorisation suspension / /

RadioStation

Wave 1 / /

URL

www.imi.europa.eu / www.catalyze.co.uk / www.imiprotect.eu / /

SocialTag